VERIFIEDET Finance·21 Sept 2026positive

Biocon arm gets positive EMA panel recommendation for breast cancerbiosimilar Pebrilzo

AI Summary

·Biocon Biologics' Pertuzumab biosimilar, Pebrilzo, received a positive recommendation from the EMA's CHMP.
·The recommendation is for the treatment of HER2-positive breast cancer.
·The European Commission will make the final decision on marketing authorisation in the EU.